Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

被引：0

作者：

Masatoshi Kudo

Takuji Okusaka

Kenta Motomura

Izumi Ohno

Manabu Morimoto

Satoru Seo

Yoshiyuki Wada

Shinpei Sato

Tatsuya Yamashita

Masayuki Furukawa

Takeshi Aramaki

Seijin Nadano

Kazuyoshi Ohkawa

Hirofumi Fujii

Toshihiro Kudo

Junji Furuse

Hiroki Takai

Gosuke Homma

Reigetsu Yoshikawa

Andrew X. Zhu

机构：

[1] Kindai University Faculty of Medicine,Department of Gastroenterology and Hepatology

[2] National Cancer Center Hospital,Graduate School of Medicine

[3] Aso Iizuka Hospital,Graduate School of Medicine

[4] National Cancer Center Hospital East,Graduate School of Medicine

[5] Kanagawa Cancer Center,undefined

[6] Kyoto University,undefined

[7] National Hospital Organization Kyushu Medical Center,undefined

[8] Kyoundo Hospital,undefined

[9] Sasaki Institute,undefined

[10] Kanazawa University,undefined

[11] National Hospital Organization Kyushu Cancer Center,undefined

[12] Shizuoka Cancer Center Hospital,undefined

[13] National Hospital Organization Shikoku Cancer Center,undefined

[14] Osaka International Cancer Institute,undefined

[15] Jichi Medical University,undefined

[16] Osaka University,undefined

[17] Kyorin University Faculty of Medicine,undefined

[18] Eli Lilly Japan K.K.,undefined

[19] Massachusetts General Hospital Cancer Center,undefined

[20] Harvard Medical School,undefined

来源：

Journal of Gastroenterology | 2020年 / 55卷

关键词：

Alpha-fetoprotein; Hepatocellular carcinoma; Japanese subanalysis; Ramucirumab; VEGFR2;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：627 / 639

页数：12

共 50 条

[11] Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An expansion cohort of the phase III REACH-2 study
Finn, R. S.
Qin, S-K.
Galle, P. R.
Wang, C.
Ogburn, K. D.
Widau, R.
Zhu, A. X.
ANNALS OF ONCOLOGY, 2020, 31 : S702 - S702
[12] Ramucirumab As Second-Line Treatment in Patients with Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein (AFP) Following Sorafenib: Pooled Results from Two Global Phase 3 Studies (REACH-2 and REACH)
Llovet, Josep M.
Kudo, Masatoshi
Finn, Richard
Galle, Peter R.
Blanc, Jean-Frederic
Okusaka, Takuji
Chau, Ian
Abada, Paolo B.
Hsu, Yanzhi
Zhu, Andrew X.
HEPATOLOGY, 2018, 68 : 166A - 166A
[13] Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Zhu, Andrew X.
Kang, Yoon-Koo
Yen, Chia-Jui
Finn, Richard S.
Galle, Peter R.
Llovet, Josep M.
Assenat, Eric
Brandi, Giovanni
Pracht, Marc
Lim, Ho Yeong
Rau, Kun-Ming
Motomura, Kenta
Ohno, Izumi
Merle, Philippe
Daniele, Bruno
Shin, Dong Bok
Gerken, Guido
Borg, Christophe
Hiriart, Jean-Baptiste
Okusaka, Takuji
Morimoto, Manabu
Hsu, Yanzhi
Abada, Paolo B.
Kudo, Masatoshi
LANCET ONCOLOGY, 2019, 20 (02): : 282 - 296
[14] Ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein following non-sorafenib-based therapy: interim results from phase 3 REACH-2 expansion cohort
Finn, R.
De Toni, E.
Yau, T. C. C.
Yen, C. -J.
Hsu, C. -H.
Chan, S.
He, A. R.
Galle, P.
Trojan, J.
Stirnimann, G.
Baron, A.
Acosta-Rivera, M.
Goyal, L.
Wang, C.
Abada, P.
Widau, R.
Zhu, A.
SWISS MEDICAL WEEKLY, 2020, : 27S - 27S
[15] Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
Zhu, A. X.
Galle, P. R.
Llovet, J. M.
Finn, R. S.
Kang, Y-K.
Yen, C. J.
Assenat, E.
Brandi, G.
Motomura, K.
Ohno, I.
Daniele, B.
Vogel, A.
Yamashita, T.
Hsu, C-H.
Meyer, T.
Widau, R.
Schelman, W.
Wang, C.
Hsu, Y.
Kudo, M.
ANNALS OF ONCOLOGY, 2019, 30
[16] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial
Kudo, Masatoshi
Hatano, Etsuro
Ohkawa, Shinichi
Fujii, Hirofumi
Masumoto, Akihide
Furuse, Junji
Wada, Yoshiyuki
Ishii, Hiroshi
Obi, Shuntaro
Kaneko, Shuichi
Kawazoe, Seiji
Yokosuka, Osamu
Ikeda, Masafumi
Ukai, Katsuaki
Morita, Sojiro
Tsuji, Akihito
Kudo, Toshihiro
Shimada, Mitsuo
Osaki, Yukio
Tateishi, Ryosuke
Sugiyama, Gen
Abada, Paolo Benjamin
Yang, Ling
Okusaka, Takuji
Zhu, Andrew Xiuxuan
JOURNAL OF GASTROENTEROLOGY, 2017, 52 (04) : 494 - 503
[17] Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
Kudo, M.
Galle, P. R.
Motomura, K.
Assenat, E.
Merle, P.
Brandi, G.
Daniele, B.
Okusaka, T.
Tomasek, J.
Borg, C.
Zagonel, V.
Morimoto, M.
Pracht, M.
Finn, R. S.
Llovet, J.
Homma, G.
Jen, M-H.
Shinozaki, K.
Yoshikawa, R.
Zhu, A. X.
ANNALS OF ONCOLOGY, 2019, 30 : 292 - 292
[18] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial
Masatoshi Kudo
Etsuro Hatano
Shinichi Ohkawa
Hirofumi Fujii
Akihide Masumoto
Junji Furuse
Yoshiyuki Wada
Hiroshi Ishii
Shuntaro Obi
Shuichi Kaneko
Seiji Kawazoe
Osamu Yokosuka
Masafumi Ikeda
Katsuaki Ukai
Sojiro Morita
Akihito Tsuji
Toshihiro Kudo
Mitsuo Shimada
Yukio Osaki
Ryosuke Tateishi
Gen Sugiyama
Paolo Benjamin Abada
Ling Yang
Takuji Okusaka
Andrew Xiuxuan Zhu
Journal of Gastroenterology, 2017, 52 : 494 - 503
[19] Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
Gilabert, Marine
Raoul, Jean-Luc
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2018, 5 : 91 - 98
[20] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
Kudo, Masatoshi
Okusaka, Takuji
Motomura, Kenta
Ohno, Izumi
Morimoto, Manabu
Seo, Satoru
Wada, Yoshiyuki
Sato, Shinpei
Yamashita, Tatsuya
Furukawa, Masayuki
Aramaki, Takeshi
Nadano, Seijin
Ohkawa, Kazuyoshi
Fujii, Hirofumi
Kudo, Toshihiro
Furuse, Junji
Takai, Hiroki
Homma, Gosuke
Yoshikawa, Reigetsu
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

← 1 2 3 4 5 →